Clinical Trials
7 trialsNCT06158841 2026-05-27
CERVINO
AbbVie
Phase 3 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT06152575 2026-05-22
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05730036 2026-03-06
LINKER-MM3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting